Victrex plc (LON:VCT)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 764.53M +25.4% |
| Revenue (ttm) | 293.90M -1.2% |
| Net Income | -19.70M |
| EPS | -0.23 |
| Shares Out | 87.08M |
| PE Ratio | n/a |
| Forward PE | 39.87 |
| Dividend | 0.60 (6.78%) |
| Ex-Dividend Date | May 28, 2026 |
| Volume | 599,629 |
| Open | 988.00 |
| Previous Close | 980.00 |
| Day's Range | 870.00 - 988.00 |
| 52-Week Range | 515.00 - 1,024.00 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 830.58 (-5.4%) |
| Est. Earnings | Dec 1, 2026 |
About Victrex
Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; and sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, aerospace, automotive, and electronics markets, as well as engages in trading activities. It serves automot... [Read more]
Financial Performance
In fiscal year 2025, Victrex's revenue was 292.70 million, an increase of 0.58% compared to the previous year's 291.00 million. Earnings were 27.80 million, an increase of 61.63%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for VCT stock is "Buy." The 12-month stock price target is 831p, which is a decrease of -5.40% from the latest price.
News
Victrex Press release: FY 2026
Victrex issued a press release on September 24, 2026, disclosing material business information to investors.
Broker Tips: Antofagasta, Renishaw, Harbour Energy, Victrex, Housebuilders
Broker tips for UK stocks that have caught our eye over the last week include Antofagasta, Renishaw, Harbour Energy and Victrex
Victrex price target raised to 1,000 GBp from 700 GBp at Citi
Citi raised the firm’s price target on Victrex (VTXPF) to 1,000 GBp from 700 GBp and keeps a Neutral rating on the shares.
Victrex price target raised to 785 GBp from 625 GBp at JPMorgan
JPMorgan analyst Chetan Udeshi raised the firm’s price target on Victrex (VTXPF) to 785 GBp from 625 GBp and keeps a Neutral rating on the shares.
Victrex price target raised to 830 GBp from 600 GBp at Deutsche Bank
Deutsche Bank raised the firm’s price target on Victrex (VTXPF) to 830 GBp from 600 GBp and keeps a Hold rating on the shares.
UK Stock Market News: Corero, Victrex, WAG Payments
Corero swings to positive EBITDA, Victrex revises FY outlook higher, optimism prevails at WAG Payment Solutions
Victrex Earnings release: Trading update
Victrex released its earnings on September 9, 2026, summarizing the period's financial results.
Victrex Earnings release: Q3 2026
Victrex released its Q3 2026 earnings on July 7, 2026, summarizing the period's financial results.
Victrex H1 Earnings Call Highlights
Victrex LON: VCT reported a modest increase in first-half revenue but lower profitability, as a weak first quarter, pricing pressure and adverse mix weighed on margins. Chief Executive Dr. James Routh...
Victrex Earnings Call Transcript: H1 2026
H1 saw modest revenue growth and strong cash flow, but margins and profits declined due to price and mix pressures. A major China plant impairment and restructuring are underway, with a new decentralized model and profit improvement plan expected to drive better performance in H2 and beyond.
Victrex Quarterly report: H1 2026
Victrex has published its H1 2026 quarterly earnings report on May 11, 2026.
Victrex Slides: H1 2026
Victrex has posted slides in relation to its H1 2026 quarterly earnings report, which was published on May 11, 2026.
Victrex price target lowered to 625 GBp from 725 GBp at JPMorgan
JPMorgan lowered the firm’s price target on Victrex (VTXPF) to 625 GBp from 725 GBp and keeps a Neutral rating on the shares.
Victrex Earnings release: Q1 2026
Victrex released its Q1 2026 earnings on February 6, 2026, summarizing the period's financial results.
Victrex Slides: ESG Presentation
Victrex has posted slides in relation to its latest quarterly earnings report, which was published on January 26, 2026.
Victrex price target lowered to 695 GBp from 880 GBp at Berenberg
Berenberg analyst Aron Ceccarelli lowered the firm’s price target on Victrex (VTXPF) to 695 GBp from 880 GBp and keeps a Hold rating on the shares.
Victrex price target lowered to 700 GBp from 740 GBp at Citi
Citi lowered the firm’s price target on Victrex (VTXPF) to 700 GBp from 740 GBp and keeps a Neutral rating on the shares.
Victrex price target lowered to 780 GBp from 850 GBp at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Victrex (VTXPF) to 780 GBp from 850 GBp and keeps a Hold rating on the shares.
Victrex Earnings Call Transcript: H2 2025
FY 2025 saw strong volume growth but limited revenue gains due to currency and mix, with profit down and robust cash conversion. A profit improvement plan aims for GBP 10 million in savings, while FY 2026 guidance targets moderate growth, margin stability, and continued CapEx discipline.
Victrex Annual report: H2 2025
Victrex has published its H2 2025 annual report on December 2, 2025.
Victrex Annual report: H2 2025
Victrex has published its H2 2025 annual report on December 2, 2025.
Victrex Slides: H2 2025
Victrex has posted slides in relation to its H2 2025 quarterly earnings report, which was published on December 2, 2025.
Victrex Earnings Call Transcript: Q3 2025
Q3 saw 8% volume growth but a 3% revenue decline due to adverse mix and medical weakness. Full-year volume guidance remains high single digits, with currency and medical spine headwinds impacting outlook. CEO transition and China facility progress highlighted.
Victrex Earnings release: Q3 2025
Victrex released its Q3 2025 earnings on July 8, 2025, summarizing the period's financial results.
Victrex Earnings Call Transcript: H1 2025
H1 2025 saw 16% volume growth and strong cash conversion, but gross margin and ASP declined due to mix and China ramp-up costs. Upgraded full-year volume guidance to high single digits, with medical and Magma programs expected to drive future growth.